Eli Lilly And Co vs Synchrony Financial — how do they compare? Eli Lilly And Co trades at $1,215.86 (market cap $1.08T), while Synchrony Financial trades at $78.8 (market cap $25.53B). The key difference: Eli Lilly And Co is far larger — about 42.3× Synchrony Financial's market cap, and Synchrony Financial pays the higher dividend (1.73%). Which is the better fit depends on your goals.
| LLY | SYF | |
|---|---|---|
Market Cap | $1.08T | $25.53B |
Sector | Health | Financials |
52-Week High | $1.24K | $88.47 |
52-Week Low | $639.43 | $63.78 |
Enterprise Value | $1.13T | — |
Dividend Yield | 0.57% | 1.73% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Synchrony Financial (SYF) trades at $78.25, up 0.08% on the day, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The stock shows robust fundamentals with a P/E of 8.05, net income margin of 23.4%, and consistent revenue around $15.0B. Recent news highlights partnerships like CareCredit with Stripe and aggressive share buybacks, while analyst consensus is strongly positive with a $86.33 price target.
The outlook for SYF is favorable due to undervaluation, earnings growth, and shareholder returns via dividends and buybacks. Risks include economic sensitivity to consumer spending and rising expenses. With no sell ratings from analysts and institutional confidence, the stock presents a solid opportunity for value-oriented investors seeking financial sector exposure.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →